ViiV Healthcare announces US FDA approval of Triumeq PD, the

ViiV Healthcare, the global specialist HIV company majority-owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. (Pfizer) and Shionogi B.V. (Shionogi) as shareholders, has announced that the U.S. Food and Drug Administration (FDA) has approved a new drug application (NDA) for a dispersible tablet formulation of the ...

Related Keywords

Shionogibv Shionogi , Deborah Waterhouse , Pfizer , Glaxosmithkline , Company Annual Report On Form , Pfizer Inc , Clinton Health Access Initiative , European Medicines Agency , Drug Administration , Viiv Healthcare , Marketing Authorisation , Elizabeth Glaser Paediatric , Saharan Africa , Safety Information , Severe Hepatomegaly With Steatosis , Fetal Toxicity , Virologic Response Due , Drug Interactions , Reconstitution Syndrome , Formulations Are Not Interchangeable , Prescribing Information , Renal Function , Annual Report ,